Managing Director & Senior Partner
Bob Lavoie is a core member of the Health Care and Principal Investors & Private Equity practices at Boston Consulting Group, where he focuses on medtech, diagnostics, and tools. Bob has been advising clients for more than 18 years on strategic, commercial, business model innovation, and transaction support matters. Bob is committed to delivering pragmatic and value-creating results for his clients.
Recently Bob has also focused on helping clients adapt to the changing health care environment that includes consolidation, value-based care, and the shift to solutions.
Bob’s work experience covers the medtech landscape, including procedure-based devices, drug delivery, and diagnostic systems and tools. He has worked with clients across all major therapeutic areas of focus, including but not limited to vascular, orthopedics, oncology, and neurology. He has also completed more than 100 diligence efforts for strategic and financial investors.
Before he joined the firm, Bob was a senior partner and managing director leading L.E.K.’s New York office and global medtech practice. He is a frequent speaker at industry conferences and contributor to industry publications on the subjects of medtech trends and provider landscape evolution.
When patients move through hospital units—and eventually are discharged—their vital information doesn’t follow. But smarter solutions can track patient data across settings.
Geoff Martha, chairman and CEO of Medtronic, highlights the innovative ways his teams addressed ventilator supply shortages, developed new products, and built strong partnerships to support the COVID medical response.
Here are some facts to clear up the confusion.
Multiple scenarios for the US and four EU countries point to a continued need for COVID-19 testing through 2024, with demand peaking in the seasonally affected first quarters of 2021 and 2022.
The medtech industry is poised for strong growth but faces challenges too. For private equity investors, making sense of the market requires understanding the range of investment themes.
Understanding how each new test works, what it can and cannot do, and when and under what circumstances it should be used is critical to avoiding confusion and misapplication.
We need better testing to get people treated and then get companies back to work.
Companies can use their clinical knowledge, digital platforms, and access to data to develop profitable portfolios of value-added services.
Extracting value from service-based businesses requires a different approach than the traditional focus on product sales.